grant
The role of immune deregulation and NGF dysmetabolism in the development of Alzheimer disease in individuals with Down syndrome
Organization UNIVERSITY OF CALIFORNIA-IRVINELocation IRVINE, UNITED STATESPosted 15 Aug 2024Deadline 31 Jul 2029
NIHUS FederalResearch GrantFY202521+ years oldA β-42A β42A-beta 42A-beta42AD dementiaAD pathologyAbeta-42Abeta42AdultAdult HumanAffectAgeAlzheimer Type DementiaAlzheimer disease dementiaAlzheimer like pathologyAlzheimer sclerosisAlzheimer syndromeAlzheimer'sAlzheimer's DiseaseAlzheimer's biomarkerAlzheimer's disease biological markerAlzheimer's disease like pathologyAlzheimer's disease pathologyAlzheimer's pathologyAlzheimers DementiaAlzheimer’s biological markerAlzheimer’s disease biomarkerAmmon HornAmyloid (Aβ) plaquesAmyloid PlaquesAmyloid beta-42Amyloid beta42Amyloid β-42Amyloid β42AmyloidosisAmyloidβ-42Amyloidβ42AstrocytesAstrocytusAstrogliaAutopsyAβ-42Aβ42BiochemicalBiologic ModelsBiologicalBiological MarkersBiological ModelsBlood PlasmaBody FluidsBrainBrain Nervous SystemBrain regionCaliforniaCanadaChromosome 21ClinicalClinical ResearchClinical StudyCognitive DisturbanceCognitive ImpairmentCognitive declineCognitive function abnormalCollaborationsCornu AmmonisDataDevelopmentDisturbance in cognitionDown SyndromeDysfunctionEncephalonEntorhinal AreaEventEvolutionFunctional disorderFutureGene TranscriptionGeneticGenetic DiseasesGenetic ModelsGenetic TranscriptionGoalsHippocampusHospitalsHumanHuman ChromosomesImageImmuneImmunesImpaired cognitionIn VitroIndividualIndividuals with down syndromeInflammationIntermediary MetabolismLangdon Down syndromeLifeLiquid substanceLive BirthMetabolic ProcessesMetabolic dysfunctionMetabolismMethodsModel SystemModelingModern ManMolecularMolecular AnalysisMongolismNerve CellsNerve DegenerationNerve Growth FactorsNerve UnitNeural CellNeuritic PlaquesNeurocyteNeurofibrillary TanglesNeuron DegenerationNeuronotrophic FactorsNeuronsNeurotrophic ProteinsNew YorkPathogenesisPathway interactionsPatientsPhysiopathologyPlasmaPlasma SerumPreventivePreventive Clinical TrialPrimary Senile Degenerative DementiaProteinsProteomicsPublishingRNA ExpressionResearchReticuloendothelial System, Serum, PlasmaRoleSenile PlaquesSpainStudy modelsTauopathiesTestingThickThicknessTranscriptionTrisomyTrisomy 21UniversitiesVulnerable Populationsaccelerated agingaccelerated biological ageaccelerated biological agingadulthoodage accelerationagesamyloid beta plaqueamyloid diseaseamyloid-b plaqueastrocytic gliaaβ plaquesbasal forebrainbio-markersbiologicbiologic markerbiomarkerbiomarker identificationbrain tissuecholinergicchromosome 21 trisomychromosome 21 trisomy syndromecognitive dysfunctioncognitive losscohortcongenital acromicria syndromecored plaquedevelopmentaldevelopmental geneticsdiffuse plaquedown syndrome individualsdown syndrome patientsentorhinal cortexextracellular vesiclesfluidfrontal cortexfrontal lobegenetic conditiongenetic disorderhippocampalidentification of biomarkersidentification of new biomarkersimagingimaging biomarkerimaging markerimaging-based biological markerimaging-based biomarkerimaging-based markerliquidmarker identificationmolecular targeted therapeuticsmolecular targeted therapiesmolecular targeted treatmentmorbus Downmulti-modalitymultidisciplinarymultimodalitynecropsyneural degenerationneural inflammationneurodegenerationneurodegenerativeneurofibrillary degenerationneurofibrillary lesionneurofibrillary pathologyneuroinflammationneuroinflammatoryneurological degenerationneuronalneuronal degenerationneuropathologicneuropathologic tauneuropathologicalneuropathological tauneuropathologynew approachesnew drug targetnew druggable targetnew markernew pharmacotherapy targetnew therapeutic targetnew therapy targetnovel approachesnovel biomarkernovel drug targetnovel druggable targetnovel markernovel pharmacotherapy targetnovel strategiesnovel strategynovel therapeutic targetnovel therapy targetpathophysiologypathwaypatient populationpatients with down syndromepeople with down syndromepostmortemprecision medicineprecision-based medicineprimary degenerative dementiapseudohypertrophic progressive muscular dystrophyresponse to therapyresponse to treatmentscRNA sequencingscRNA-seqsenile dementia of the Alzheimer typesingle cell RNA-seqsingle cell RNAseqsingle cell expression profilingsingle cell transcriptomic profilingsingle-cell RNA sequencingsocial roletangletargeted biomarkertau associated neurodegenerationtau associated neurodegenerative processtau driven neurodegenerationtau induced degenerationtau induced neurodegenerationtau mediated neurodegenerationtau neurodegenerative diseasetau neuropathologytau pathologytau pathophysiologytau proteinopathytau related neurodegenerationtau-induced pathologytauopathic neurodegenerative disordertauopathytherapeutic responsetherapy responsetranscriptomicstreatment responsetreatment responsivenesstrisomy 21 syndromevulnerable groupvulnerable individualvulnerable people
Description preview
PROJECT SUMMARY/ABSTRACT
Down syndrome (DS) is a developmental genetic condition caused by trisomy of human chromosome 211-6. DS occurs
in approximately 1 in 600-1000 live births and affects more than 300,000 individuals in the USA. Neuropathological
and clinical features of Alzheimer’s disease (AD) present early in life through the seventh decade…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click